Aneurysmal SAH has an incidence rate of 8 cases per 100,000 persons per year in the UK. Although this accounts for only 5% of all strokes in the UK, aneurysmal SAH is of significant clinical and socioeconomic importance because it particularly affects those who are relatively young (median age 52 years) and thus has a disproportionate effect on the loss of productive life. The early mortality rate reaches 20%, and only 47% of patients are discharged directly home after successful interventions, with the rest needing further care in the referring hospital or a rehabilitation unit. The overall unfavorable outcome is as high as 38%, which is associated with older patients as well as those with poor clinical grades and high Fisher grades on CT scans, larger aneurysms or aneurysms located on the posterior circulation, and comorbidities (for example, hypertension or ischemic heart disease). Within the UK, this means that there are approximately 3500 patients with aneurysmal SAH either dying or sustaining severe disabilities every year.

Cerebral autoregulation is an intrinsic self-defense mechanism against secondary ischemia that maintains a stable blood flow during fluctuations of the cerebral perfusion pressure. Impaired autoregulation has been known to correlate with poor outcome after head injuries. Indeed, daily assessment of autoregulation helps identify patients and situations associated with high risk of secondary ischemia. Autoregulation can be measured conveniently at the bedside by using the THRT on TCD ultrasonography. When the THRT is used for day-to-day assessments after aneurysm clip placement, there is a relationship with the clinical outcome. Another noninvasive measurement of autoregulation is the pressure-reactivity index, which is a moving correlation coefficient between the ICP and the mean arterial pressure. A pressure-reactivity index value greater than 0.2 has been found to reflect poor cere-
browascular reactivity and a value less than –0.2 demonstrates excellent reactivity in patients with head injuries. However, whether the pressure-reactivity index can be applied in cases of aneurysmal SAH is unclear.

We have previously demonstrated that acute treatment with pravastatin ameliorates cerebral vasospasm and reduces the incidence of related DINDs and death in patients following aneurysmal SAH. In this study, we assess the hypothesis that these effects were associated with improved autoregulation as defined using the THRT and pressure-reactivity index, and we explore the predictive value and mutual association between these indices.

Clinical Material and Methods

Patient Population

Data relating to clinical course, bedside monitoring, and TCD indices were extracted from the pravastatin trial. In this double-blind study, 80 patients between the ages of 18 and 84 years who had an aneurysmal SAH and who were admitted to the Department of Neurosurgery, Addenbrooke’s Hospital were randomized to receive either 40 mg of pravastatin sodium (Lipostat; Bristol-Myers Squibb Pharmaceuticals, Ltd., Hounslow, Middlesex, UK) or placebo (lactose) once daily. Trial medications were begun within 72 hours of ictus and continued for up to 14 days. Baseline data included age, sex, medical history, and initial aneurysmal SAH grade according to the World Federation of Neurosurgical Societies. Radiological information included the Fisher grade on CT scans, presence of hydrocephalus and/or intraventricular hemorrhage, and aneurysm location on cerebral angiography. Exclusion criteria were noneurysmal SAH, pregnancy, preictal statin therapy, and contraindications to statin use (for example, history of liver or renal dysfunction, or alanine aminotransferase level > 50 U/L). After admission, the clinical management of the condition in each patient followed department standards, including the administration of nimodipine and moderate intravenous fluid supplement. When there were clinical indications for continuous ICP monitoring, patients were admitted to the neurosciences critical care unit and an ICP probe (Codman MicroSensor; Johnson & Johnson Medical, Ltd., Berkshire, UK) or an external ventricular drain was inserted into the nondominant frontal region. For symptomatic vasospasm salvage, “triple-H” therapy was administered. None of the patients underwent endovascular angioplasty (balloon angioplasty or endovascular vasodilator therapy). Factors that might affect the outcome were documented, including ventriculitis, sepsis, mode of aneurysm treatment (endovascular compared with clip placement), and immediate postoperative deficits.

Examinations Using TCD Ultrasonography

We adopted daily TCD ultrasonography (DWL MultiDop X4; DWL Elektronische Systeme GmbH, Singen, Germany) performed using a 2-MHz probe mounted on a specially designed head frame as a surrogate method to measure cerebral vasospasm. Systolic, diastolic, and mean flow velocities in both MCAs were captured (50- to 60-mm depths) and recorded using in-house designed BioSan software. Vasospasm and severe vasospasm were defined as demonstrating values of greater than 1.2 and 2 m/sec- ond, respectively, with the Lindegaard ratio for both greater than 3, which has high predictive values for the presence of significant vasospasm on cerebral angiography.

Examinations for Cerebral Autoregulation

Detailed methods for the assessment of cerebral autoregulation by using the THRT and pressure-reactivity index have been described in previous publications. The THRT is calculated as follows: THRT = (FV_{baseline} - FV_{hyperemia}) / FV_{baseline}. The pressure-reactivity index was calculated as a moving correlation coefficient between 40 consecutive onds with a 2-minute interval were performed after a minimum of a 10-second baseline data recording. The criteria for an acceptable THRT score included a sudden decrease in MCA flow velocity at the onset of compression, a stable TCD signal during compression, and a minimum of 30% decrease in flow velocity with no blood pressure instability. The THRR is calculated as follows: THRR = (FV_{baseline} - FV_{hyperemia}) / FV_{baseline}. The pressure-reactivity index was calculated as a moving correlation coefficient between 40 consecutive samples of mean values for ICP and arterial blood pressure averaged for a period of 6 seconds. The data were averaged for the whole period of recordings obtained from Days 0 to 5.

Definition of DIND and Outcome

Vasospasm-related DIND was defined as development of focal neurological deficits and/or a drop in the Glasgow Coma Scale score by 2 points or more and was associated with severe vasospasm on TCD ultrasonography. Other conditions that could have caused neurological deterioration in the study patients (for example, hydrocephalus, intracerebral hemorrhage, surgical complications, metabolic abnormalities, infection) were excluded using repeated imaging (CT, xenon CT, and/or cerebral angiography) and metabolic screening. Immediate postoperative deficits were defined as new neurological deficits that were evident on recovery from general anesthesia. Patient disability at discharge was recorded according to the modified Rankin Scale as favorable (score of 1 or 2) or unfavorable (score of 3–6).

Statistical Analysis

All analyses were performed on an intention-to-treat basis, and probability values were two-sided. Data were presented as the mean and with 95% CIs. Analysis was performed using statistical software (STATA Intercooled 8.0 for Windows; STATA Corp., College Station, TX). Analysis was performed separately on the side ipsilateral and the one contralateral to the ruptured aneurysm. The THRR and the maximum mean flow velocity of the MCA were averaged every 3 days from Days 0 to 14. Daily pressure-reactivity index results from each patient were averaged to produce a patient-oriented database to satisfy the independence assumption for linear regression. Data were compared between the pravastatin and placebo groups and between patients with or without vasospasm, DINDs, or unfavorable outcome on the t-test. Probability values less than 0.05 were considered significant.
Results

Patient Data

Trial medication was begun within 1.8 days (95% CI 0–4.3 days) after the ictus. Forty-two (52.5%) of the 80 patients demonstrated vasospasm on TCD ultrasonography, including 25 (62.5%) of the 40 patients who received placebo and 17 (42.5%) of the 40 who received pravastatin. Nineteen (23.8%) of the 80 patients had severe vasospasm, including 12 (30%) of the 40 who received placebo and seven (17.5%) of the 40 who received pravastatin. Vasospasm-related DINDs occurred in 14 (17.5%) of the 80 patients (12 [30%] of the 40 patients who received placebo and two [5%] of the 40 patients who received pravastatin) and were associated with new cerebral infarcts on CT scans. Daily THRRs were available for all but one patient, in whom the image quality was unsatisfactory for interpretation because of a thicker temporal bone on the contralateral side. All 80 patients were included for the final analysis of THRR compared with vasospasm incidence, DINDs, and effects of statins. Thirty-one of the 32 patients with ICP monitoring or external ventricular drainage had suitable data for pressure-reactivity index assessment. These patients were examined during the acute postictus period when intensive care was required. Therefore only 15% of the THRT data overlapped with data from the pressure-reactivity index examinations (132 of nearly 800).

The TCD-Derived Autoregulation Index and Statin Treatment

On Day 0, no difference in the TCD-derived autoregulation indices was found between the two groups. Patients in the pravastatin group had a shortened duration of autoregulation impairment on both sides (ipsilateral side: 3.0 days, 95% CI 1.9–4.1 days; contralateral side: 1.6 days, 95% CI 0.9–2.3 days) compared with those in the placebo group (ipsilateral side: 5.3 days, 95% CI 3.9–6.8 days; contralateral side: 3.7 days, 95% CI 2.3–5.1 days). The mean number of days by which the impairment was shortened was 2.4 days (95% CI 3.2–5.1 days, p = 0.011) for the ipsilateral side and 2.08 days (95% CI 0.6–3.6 days, p =
For the contralateral (Fig. 2). After Day 3, the THRR on both sides was consistently higher in the pravastatin group (Fig. 3). The maximum differences were +9% (95% CI +1.8 to +16.2%, Days 9–11, p = 0.013) on the ipsilateral side and +13.9% (95% CI +5.2 to +12.3%, Days 12–14, p = 0.002) on the contralateral.

**Correlation Among Autoregulation Indices and Mean Blood Flow Velocity**

There was a negative correlation between the pressure-reactivity index and the ipsilateral THRR from Day 3 to Day 5 (r = –0.635, p = 0.008); a similar correlation, but one of borderline significance, was found between the pressure-reactivity index and the contralateral THRR (r = –0.748, p = 0.064). There were significantly negative correlations between the THRR and the mean flow velocity of the ipsilateral MCA from Day 0 to Day 14 (r = –292.14 to –143.69, p = 0.002), and similar correlations were found on the contralateral side after Day 3 (r = –204.54 to –77.64, p ≥ 0.05) but not during the acute period (Days 0–3). Correlations between the pressure-reactivity index and mean flow velocity can be seen on both sides (r ~ 0.40, p < 0.02).

**Correlations Among Autoregulation Indices and Patients With and Without Vasospasm, DINDs, and Unfavorable Outcome**

No significant difference was found between the patients with good and poor grades in terms of their initial THRT responses, THRRs, pressure-reactivity index scores, and durations of impaired autoregulation. In patients who had severe vasospasm on the ipsilateral side, the corresponding THRR was significantly lower from Day 0 to Day 14, reaching the maximum level on Days 9 to 11 (–10.8%, 95% CI –4.2 to –18.3%, p = 0.002), and the THRR on the contralateral side was lower during the period of DIND (Days 9–11, –11.2%, 95% CI –2.4 to –20%, p = 0.016, Fig. 4). Therefore, onsets of DINDs occurred around the time when the THRR on both sides significantly decreased (Days 9–11). Patients with vasospasm, severe vasospasm, DINDs, or unfavorable outcome had...
Effects of statins on cerebral autoregulation after aneurysmal SAH

**TABLE 1**

Comparison in durations of impaired autoregulation in patients with aneurysmal SAH

<table>
<thead>
<tr>
<th>Side</th>
<th>Days of Autoregulation</th>
<th>Impairment (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ipsilat</td>
<td>w/</td>
<td>6.4 (5.0–7.8)</td>
<td>2.1 (1.2–3.0)</td>
</tr>
<tr>
<td></td>
<td>w/o</td>
<td>8.2 (6.6–9.7)</td>
<td>3.1 (2.1–4.0)</td>
</tr>
<tr>
<td></td>
<td>w/o</td>
<td>8.6 (6.8–10.4)</td>
<td>3.2 (2.3–4.1)</td>
</tr>
<tr>
<td></td>
<td>w/o</td>
<td>5.2 (3.8–6.7)</td>
<td>3.2 (2.0–4.3)</td>
</tr>
<tr>
<td>contralat</td>
<td>w/</td>
<td>4.2 (2.4–6.0)</td>
<td>2.1 (1.2–2.9)</td>
</tr>
<tr>
<td></td>
<td>w/o</td>
<td>4.6 (2.0–7.3)</td>
<td>2.4 (1.6–3.3)</td>
</tr>
<tr>
<td></td>
<td>w/o</td>
<td>5.0 (2.2–7.8)</td>
<td>2.2 (1.4–2.9)</td>
</tr>
<tr>
<td></td>
<td>w/o</td>
<td>3.0 (1.7–4.2)</td>
<td>2.4 (1.4–3.4)</td>
</tr>
</tbody>
</table>
* Assessed using TCD ultrasonography.

significantly longer durations of impaired autoregulation as measured by the THRT, particularly on the ipsilateral side, compared with those without such events (Table 1).

**Discussion**

Effective compensatory mechanisms of cerebral blood flow are important for avoiding cerebral ischemia during vasospasm. For patients in this study who experienced DINDs, autoregulation in both the ipsilateral and contralateral sides failed simultaneously. In this situation, acute resuscitation by induced hypertension and intravascular volume enhancement may lead to rapid development of cerebral edema. Thus, effective therapy for preventing or treating vasospasm-related DINDs should be oriented to improving autoregulation.

Why is autoregulation lost after aneurysmal SAH-induced vasospasm? The early onset of impaired autoregulation seen in poor-grade patients is closely associated with severe vasospasm and cerebral infarcts, implying that the load of subarachnoid blood is the cause of these complications. The negative correlation between the THRT and the mean flow velocity of the MCA indicates that high-speed blood flow causes adverse effects on cerebral autoregulation. Excessive flow velocities during vasospasm have been known to produce greater shear force on the vascular wall, potentially interfering with endothelial function. Therefore, there seems to be a cycle of adverse events following endothelial damage, including autoregulation impairment, vasospasm, and eventual cerebral ischemia.

The direct contact between oxyhemoglobin from subarachnoid blood and cerebrovascular adventitia also may be important because it results in denervation and loss of neurogenic control of cerebral arteries, a depletion of endothelium-derived nitric oxide, and an increased production of endothelin. Impaired activation of the potassium channels in vascular smooth muscle and enhanced platelet aggregation and leukocyte adhesion are also implicated.

In this 14-day trial, we found that pravastatin therapy can effectively ameliorate vasospasm, including its incidence, duration, and severity. Conversely, patients in whom pravastatin was discontinued seemed to start to suffer vasospasm-related DINDs. These findings indicate that these vascular effects are prompt and relatively short-lived. Therefore, future trials of statins with aneurysmal SAH may have to adopt courses of 3 or more weeks.

We did not find predictive functions for the pressure-reactivity index in terms of clinical outcome and adverse events among patients with aneurysmal SAH that were similar to those seen in patients with head injuries. This is probably because of the relatively small sample of 32 patients or the shorter duration of measurement (Days 0–5), which failed to correlate with data on vasospasm. Another possibility is that the ICP-derived property of the pressure-reactivity index cannot detect efficiently the side difference of vasospasm-related complications. Therefore, the value of the pressure-reactivity index measurement in patients with aneurysmal SAH will need to be assessed in a larger group of patients or a study of longer durations of ICP measurements, principally for those patients presenting in coma, for whom ICP monitoring is more routine.

**Conclusions**

In this study, we have shown that the neuroprotective effects of acute treatment with pravastatin following aneurysmal SAH are associated with the enhancement of normal autoregulation. A routine and daily assessment of cerebral autoregulation by using THRT may help identify patients at high risk of DINDs. An assessment in which the pressure-reactivity index is used in the acute phase after aneurysmal SAH is less helpful in this respect.

**Disclaimer**

None of the authors has a financial interest in the devices used in this study.

**References**

3. Czosnyka M, Smielewski P, Kirkpatrick P, Laing RJ, Menon D,


Dr. Ming-Yuan Tseng was supported by the Raymond and Beverly Sackler Studentship, University of Cambridge. This project was sponsored by the Addenbrooke’s Hospital National Health Services Trust and the University of Cambridge Dr. Marek Czosnyka is on unpaid leave from Warsaw University of Technology, Poland.

Manuscript received July 10, 2006. Accepted in final form August 18, 2006.

Address reprint requests to: Ming-Yuan Tseng, M.D, M.Phil, M.Sc, Box 167, Department of Neurosurgery, Addenbrooke’s Hospital, Cambridge CB2 2QQ, United Kingdom. email: mty22@cam.ac.uk.